These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 10188630)
41. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Joyce JN Synapse; 2001 May; 40(2):137-44. PubMed ID: 11252025 [TBL] [Abstract][Full Text] [Related]
42. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Rupniak NM; Kilpatrick G; Hall MD; Jenner P; Marsden CD Psychopharmacology (Berl); 1984; 84(4):512-9. PubMed ID: 6441952 [TBL] [Abstract][Full Text] [Related]
43. Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment. Smith RC; Davis JM Psychopharmacol Commun; 1975; 1(3):285-93. PubMed ID: 1241453 [TBL] [Abstract][Full Text] [Related]
44. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity. De Veaugh-Geiss J; Devanand DP; Carey RJ Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268 [TBL] [Abstract][Full Text] [Related]
46. A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine. Jelovac N; Sikirić P; Rucman R; Petek M; Perović D; Konjevoda P; Marović A; Seiwerth S; Grabarević Z; Sumajstorcić J; Dodig G; Perić J Biol Psychiatry; 1998 Apr; 43(7):511-9. PubMed ID: 9547930 [TBL] [Abstract][Full Text] [Related]
47. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity. Lublin H; Gerlach J; Peacock L Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047 [TBL] [Abstract][Full Text] [Related]
48. Chronic haloperidol treatment potentiates apomorphine- and ethanol-induced hypothermia in the rat. Lai H; Kazi MS; Carino MA; Horita A Life Sci; 1982 Mar; 30(10):821-6. PubMed ID: 7200179 [TBL] [Abstract][Full Text] [Related]
49. Treatment with GM1 ganglioside reverses dopamine D-2 receptor supersensitivity induced by the neurotoxin MPTP. Hadjiconstantinou M; Weihmuller F; Neff NH Eur J Pharmacol; 1989 Sep; 168(2):261-4. PubMed ID: 2532603 [TBL] [Abstract][Full Text] [Related]
50. Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding. Pierce RC; Rowlett JK; Bardo MT; Rebec GV Neuroscience; 1991; 45(2):373-8. PubMed ID: 1762684 [TBL] [Abstract][Full Text] [Related]
51. Carbamazepine reduces dopamine-mediated behavior in chronic neuroleptic-treated and untreated rats: implications for treatment of tardive dyskinesia and hyperdopaminergic states. LaHoste GJ; Wigal T; King BH; Schuck SEB; Crinella FM; Swanson JM Exp Clin Psychopharmacol; 2000 Feb; 8(1):125-132. PubMed ID: 10743913 [TBL] [Abstract][Full Text] [Related]
52. Effects of ritanserin on haloperidol-induced dopamine (D2) receptor up-regulation in the rat. Szczepanik AM; Wilmot CA Neurosci Lett; 1997 Aug; 231(2):91-4. PubMed ID: 9291148 [TBL] [Abstract][Full Text] [Related]
53. Dopaminergic and cholinergic interaction in cataleptic responses in mice. Ushijima I; Kawano M; Kaneyuki H; Suetsugi M; Usami K; Hirano H; Mizuki Y; Yamada M Pharmacol Biochem Behav; 1997 Sep; 58(1):103-8. PubMed ID: 9264077 [TBL] [Abstract][Full Text] [Related]
54. Permanent haloperidol-induced dopamine receptor up-regulation in the ovariectomized rat. Fields JZ; Gordon JH Brain Res Bull; 1991 Apr; 26(4):549-52. PubMed ID: 1831063 [TBL] [Abstract][Full Text] [Related]
55. Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine. Ito C; Onodera K; Sakurai E; Sato M; Watanabe T J Pharmacol Exp Ther; 1996 Oct; 279(1):271-6. PubMed ID: 8859003 [TBL] [Abstract][Full Text] [Related]
56. No change in dopamine D1 receptor in vivo binding in rats after sub-chronic haloperidol treatment. Sanci V; Houle S; DaSilva JN Can J Physiol Pharmacol; 2002 Jan; 80(1):36-41. PubMed ID: 11911224 [TBL] [Abstract][Full Text] [Related]
57. Neuroleptic-induced supersensitivity and brain iron: I. Iron deficiency and neuroleptic-induced dopamine D2 receptor supersensitivity. Ben-Shachar D; Youdim MB J Neurochem; 1990 Apr; 54(4):1136-41. PubMed ID: 1968955 [TBL] [Abstract][Full Text] [Related]
58. Differential alteration in striatal dopaminergic and cortical serotonergic receptors induced by repeated administration of haloperidol or centbutindole in rats. Gulati A; Srimal RC; Dhawan BN Pharmacology; 1988; 36(6):396-404. PubMed ID: 2901759 [TBL] [Abstract][Full Text] [Related]